obesity

  1. Novo Nordisk reports first quarter results

    Novo Nordisk says pricing pressure within diabetes to continue, especially in the US. First quarter 2019 results: Sales from North America Operations declined 4% on constant exchange rates.
    • anonymous
    • Thread
    • biopharma diabetes gilead sciences insulin merck novo nordisk obesity pfizer pharmaceutical sanofi
    • Replies: 3
    • Forum: Novo Nordisk

  2. Obesity drug developer took a big step toward FDA approval

    Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help patients reduce caloric...
Top Bottom
Back